CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Astex Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Astex Pharmaceuticals Inc
Suite 200, 4140 Dublin Blvd.
Phone: (925) 560-0100p:925 560-0100 DUBLIN, CA  94568  United States Ticker: ASTXASTX

This company was Merged or Acquired on 10/11/2013.
This company ceased filing statements with the SEC on 12/31/2013.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Astex Pharmaceuticals, Inc., formerly SuperGen, Inc. is a pharmaceutical company. The Company is primarily engaged in the discovery and development of small molecule therapeutics with a focus on oncology and hematology. The Company is developing a pipeline of medicines for partnership with pharmaceutical companies. It is also engaged in the application of fragment-based drug discovery and development of small-molecule therapeutics. Using its fragment-based drug discovery platform, Pyramid, Astex Therapeutics Limited, a wholly owned subsidiary, has built a pipeline of molecularly-targeted drugs for large pharmaceutical partners and internal development that are at various stages of clinical, pre-clinical and early discovery development. In October 2013, Otsuka Holdings Co Ltd announced that its wholly owned subsidiary, Otsuka Pharmaceutical Co., Ltd completed, through its wholly owned indirect subsidiary Autumn Acquisition Corporation, its acquisition of Astex Pharmaceuticals, Inc.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/201312/31/2012YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer James S.Manuso 64 7/20/2011 2/27/2001
President, Director HarrenJhoti 50 7/20/2011 7/20/2011
Independent Vice Chairman of the Board Peter J.Fellner 70 7/20/2011 7/20/2011
8 additional Officers and Directors records available in full report.

Business Names
Business Name
Astex Therapeutics Limited
ASTX

General Information
Number of Employees: 136 (As of 12/31/2012)
Outstanding Shares: 94,943,230 (As of 8/1/2013)
Shareholders: 482
Stock Exchange: NASD
Federal Tax Id: 911841574
Fax Number: (925) 560-0101
Email Address: investor_relations@supergen.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023